Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

The results of an observational study published in JMBR and funded by the Health Technology Assessment Programme shows that bisphosphonate use is associated with a greater risk of chronic kidney disease progression.

Research scientists working in laboratory

Bisphosphonates, a drug class used to prevent the loss of bone density, are the first-line treatment for preventing fracture in osteoporosis patients. Osteoporosis is often associated with patients with chronic kidney disease (CKD), who can suffer from low bone density and increased fracture risk, but there was little information available on the safety of bisphosphonates in patients with CKD.

Moderate to severe (stages 3-5) chronic kidney disease (CKD) affects up to 2.8 million people in the UK and 2.7 million people in Spain.

The Prieto-Alhambra Group for Pharmaco- and Device Epidemiology at Nuffield Department of Orthopaedics, Rheumatology & Musculoskeletal Sciences (NDORMS), in collaboration with SIDIAP, set out to understand the safety profile of bisphosphonates in patients with moderate to severe CKD. Using primary-care electronic records from two patient cohorts in the UK and Catalonia, Spain, they analysed the data from 4,000 bisphosphonate users and more than 15,000 non-users.

Read the full story on the NDORMS website

Similar stories

Eoghan Mulholland receives prestigious Lee Placito Research Fellowship

Awards and Appointments General

Dr Eoghan Mulholland has received the prestigious Lee Placito Research Fellowship in Gastrointestinal Cancer. Eoghan will use this 3-year position to research cell interactions in colorectal cancers.

Eleven Oxford professors honoured by the Academy of Medical Sciences

Awards and Appointments General

The Academy of Medical Sciences has elected 11 University of Oxford biomedical and health scientists to its fellowship.

3,400 different medicines used globally to treat COVID-19

Coronavirus COVID-19 General Research

Insufficient data, and misleading recommendations led to significant early heterogeneity in global COVID-19 patient management, according to recent BMJ study.

Children and Adolescents’ Mental Health: One Year On

Coronavirus COVID-19 General Research

Parents and carers reported that behavioural, emotional and attentional difficulties in their children changed considerably throughout the past year, increasing in times of national lockdown and decreasing as restrictions eased and schools reopened, according to the latest Co-SPACE (COVID-19 Supporting Parents, Adolescents, and Children in Epidemics) study, led by experts at the University of Oxford.

Tackling climate concerns through sustainable healthcare

General

A new initiative by Oxford Medical Students and faculty is accelerating the learning of sustainable healthcare at Oxford.

Future-Proofing Mental Health

General Research

UK academics are calling for targets for mental health research in order to meet the healthcare challenges of the next decade. Published today in Journal of Mental Health, researchers set out four overarching goals that will speed up implementation of mental health research and give a clear direction for researchers and funders to focus their efforts when it comes to better understanding the treatment of mental health.